Company Information
Frequency Therapeutics was founded on January 2015. The company is based in Woburn, MA, USA . The number of employees in Frequency Therapeutics is less than 50. Frequency therapeutics develops small molecule drugs that activate progenitor cells within the body to restore healthy tissue.Here is how Frequency Therapeutics describes itself: "Frequency Therapeutics is actively working to transform the treatment of hearing loss. Learn more about our approach to degenerative diseases."
Funding & investors
Frequency Therapeutics has received 6 rounds of venture funding. The total funding amount is around $180.3M. Last venture funding round was $42.3M, announced on July, 2020.- Perceptive Advisors (Hedge fund)
- Cobro Ventures (Venture capital)
- RTW Investments LLC (Hedge fund)
- Mizuho Securities Principal Investment (Venture capital)
- Axil Capital (Venture capital)
- Contact us if you are interested to see all 20 investors
Similar Companies [beta]
- 4d molecular therapeutics
- Oncorus
- Revivemed
- Twentyeight seven therapeutics
- Encoded therapeutics
- Talaris therapeutics
- More...
Venture Categories
Active Venture Investors
- Active Investors in Biotechnology
- Active Investors in Health Care
- Active Investors in Science And Engineering
- Active Investors in Wellness
Venture Competitors
- Best Funded Biotechnology Startups
- Best Funded Health Care Startups
- Best Funded Science And Engineering Startups
- Best Funded Wellness Startups
News
Frequency Therapeutics - Blog
- Frequency Therapeutics to Participate in 2022 H.C. Wainwright Global Investment Conference
- Frequency Therapeutics Provides Business Updates and First Quarter 2022 Financial Results
- Frequency Therapeutics to Participate in B. Riley Securities’ Neuro & Ophthalmology Investor Conference
- Frequency Therapeutics Provides Business Updates and Reports Fourth Quarter and Full Year 2021 Financial Results
- Frequency Therapeutics to Participate in Upcoming March 2022 Investor Conferences
- Frequency Therapeutics to Present 2022 Business and Pipeline Overview at the 40th Annual J.P. Morgan Healthcare Conference
LEXINGTON, Mass. –(BUSINESS WIRE)–May 18, 2022– Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage regenerative medicine company focused on developing therapeutics to activate a person’s innate regenerative potential to restore function, today announced that Chief Scientific OfficerThe post Frequency Therapeutics to Participate in 2022 H.C. Wainwright Global Investment Conference appeared first on Frequency Therapeutics.
FX-322-208 Phase 2b Study in Individuals with Acquired Sensorineural Hearing Loss Remains on Track for a Readout in Q4 2022 or Q1 2023 Reports Cash and Cash Equivalents of $124.8M , Providing Runway into 2024; Funds Enable Company to Meet Multiple Clinical Milestones for Programs Targeting HearingThe post Frequency Therapeutics Provides Business Updates and First Quarter 2022 Financial Results appeared first on Frequency Therapeutics.
LEXINGTON, Mass. –(BUSINESS WIRE)–Apr. 22, 2022– Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage regenerative medicine company focused on developing therapeutics to activate a person’s innate regenerative potential to restore function, today announced that Chief Scientific OfficerThe post Frequency Therapeutics to Participate in B. Riley Securities’ Neuro & Ophthalmology Investor Conference appeared first on Frequency Therapeutics.
Company Reports Steady Enrollment for FX-322-208 Phase 2b Study in Individuals with Sudden and Noise-Induced Sensorineural Hearing Loss; Topline Results Anticipated in Q4 2022 or Q1 2023 Continued Progress on Second Program for Hearing Restoration , FX-345; Phase 1b Start Anticipated in H2 2022The post Frequency Therapeutics Provides Business Updates and Reports Fourth Quarter and Full Year 2021 Financial Results appeared first on Frequency Therapeutics.
LEXINGTON, Mass. –(BUSINESS WIRE)–Feb. 28, 2022– Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage regenerative medicine company focused on developing therapeutics to activate a person’s innate regenerative potential to restore function, today announced that Chief Executive OfficerThe post Frequency Therapeutics to Participate in Upcoming March 2022 Investor Conferences appeared first on Frequency Therapeutics.
Company to Review Milestones for its Phase 2b Study of FX-322, the Near-Term Clinical Plan for its Second Hearing Restoration Asset, FX-345, and Selection of a Lead Candidate for its Novel Multiple Sclerosis Program that Has Shown Potent Pre-Clinical Data LEXINGTON, Mass. –(BUSINESS WIRE)–Jan.The post Frequency Therapeutics to Present 2022 Business and Pipeline Overview at the 40th Annual J.P. Morgan Healthcare Conference appeared first on Frequency Therapeutics.
Share:
